Moreover, it needs to be tested whether losartan can potentiate the response to PD-(L)1 blockade in other cancers associated with peritumoral fibrosis and desmoplasia, such as pancreatic cancer and intrahepatic cholangiocarcinoma, which so far have been refractory to ICI. Here, CD274 is linked to intrahepatic cholangiocarcinoma.